Cell and gene therapy is the hottest area in biotech at the moment, and Gilead’s $11.9bn acquisition of Kite Pharma in October has been followed by Celgene’s $9bn buyout of Juno Therapeutics.

Novartis has doubled down on its gene therapy collaboration with Voyager Therapeutics, stumping up another $1.2 billion-plus in potential milestone payments and directing the partnership at two ...

Novartis (NYSE:NVS) (OTCPK:NVSEF) announced Thursday the acquisition of Kate Therapeutics, a San Diego-based gene therapy ...

TThe pharmaceutical company Novartis has disclosed to the US Food and Drug Administration that some testing data for its newly approved gene therapy were manipulated, the agency announced Tuesday ...

(RTTNews) - Novartis AG (NVS), Wednesday, announced the positive results from its Phase III clinical program of investigational gene replacement therapy, intrathecal onasemnogene abeparvovec or ...